Hépato-Gastro & Oncologie Digestive
MENUEarly Crohn's disease Volume 22, supplement 2, Octobre 2015
Figures
CHU Hôtel Dieu,
Institut des Maladies de l’Appareil Digestif,
1 place A. Ricordeau,
44093 Nantes,
France
Institut des Maladies de l’Appareil Digestif,
1 place A. Ricordeau,
44093 Nantes,
France
* Tirés à part
- Key words: Crohn's disease, anti-TNF, biotherapy, intestinal damage
- DOI : 10.1684/hpg.2015.1185
- Page(s) : 11-5
- Published in: 2015
The early Crohn's disease is a particular entity during which, no intestinal damage is present. The patients, during this limited phase of their disease, are more susceptible to obtain a benefit from a biotherapy. Indeed, the proportion of patients obtaining a deep remission, clinic and endoscopic, is significantly higher in early Crohn's disease compared to the patients with a long duration of their disease. However, major points remained unresolved. First, it has not been demonstrated that obtaining a deep remission could modify the natural history of the disease in a long term. The second point is the difficulty to discriminate patients at risk of severe disease in whom beginning a biotherapy could be appropriate.